EcoDrugPlus

Coagulation Factor Ii (Thrombin) Receptor

Ensembl ID : ENSSPAG00000021094
Gene Symbol: F2R
1 Cross references
216 Possible Orthologues:

Coagulation Factor Vii

Ensembl ID : ENSSPAG00000017436
Gene Symbol: F7
3 Cross references
240 Possible Orthologues:

Coagulation Factor Vii, Like

Ensembl ID : ENSSPAG00000017344
Gene Symbol: F7L
1 Cross references
78 Possible Orthologues:

Coagulation Factor Xi-Like

Ensembl ID : ENSSPAG00000019531
Gene Symbol: LOC103361506
2 Cross references
212 Possible Orthologues:

Coiled-Coil Domain Containing 6

Ensembl ID : ENSSPAG00000015469
Gene Symbol: CCDC6
3 Cross references
207 Possible Orthologues:

Collagenase 3-Like

Ensembl ID : ENSSPAG00000017534
Gene Symbol: LOC103370389
2 Cross references
274 Possible Orthologues:

Collagenase 3-Like

Ensembl ID : ENSSPAG00000017400
Gene Symbol: LOC103370393
2 Cross references
111 Possible Orthologues:

Collagenase 3-Like

Ensembl ID : ENSSPAG00000017569
Gene Symbol: LOC103370390
2 Cross references
275 Possible Orthologues:

Colony Stimulating Factor 1 Receptor

Ensembl ID : ENSSPAG00000000870
Gene Symbol: CSF1R
3 Cross references
63 Possible Orthologues:

Complement C5

Ensembl ID : ENSSPAG00000022435
Gene Symbol: C5
2 Cross references
216 Possible Orthologues:

Corticotropin Releasing Hormone Receptor 1

Ensembl ID : ENSSPAG00000002184
Gene Symbol: CRHR1
2 Cross references
207 Possible Orthologues:

Cyclin D1

Ensembl ID : ENSSPAG00000005339
Gene Symbol: CCND1
3 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).